Back to Journals » OncoTargets and Therapy » Volume 6
Expression of novel tumor markers of pancreatic adenocarcinomas in intrahepatic cholangiocarcinomas
Received 28 October 2012
Accepted for publication 6 December 2012
Published 11 January 2013 Volume 2013:6 Pages 19—23
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 5
Meijuan Zong,1 Lei Jia,1 Liang Li2
1Zibo Vocational Institute, 2Department of General Surgery, Zibo Central Hospital, Zibo, China
Abstract: Intrahepatic cholangiocarcinomas (IHCCs) are morphologically and biologically similar to pancreatic ductal adenocarcinomas (PDACs), so newly identified PDAC-associated genes or proteins could provide clues for screening novel biomarkers for IHCC. In this study, the expression of three novel PDAC tumor markers (T-box transcription factor-4 [TBX4], heat shock protein-60 [HSP60], and Parkinson protein-7 [DJ-1]) identified in previous proteomic studies in IHCC tumors were immunohistochemically detected. The current study confirmed that three novel pancreatic cancer biomarkers TBX4, HSP60, and DJ-1 were also overexpressed in IHCC tumors, but with a relatively lower expression level than PDAC. No significant association was found between tumor marker expression and the clinicopathological characteristics of IHCC patients except that TBX4 expression correlated with tumor grades. Moreover, DJ-1 was demonstrated to be an independent prognostic factor for these patients. The current findings suggest that DJ-1 might play an important role in the malignant progression of IHCC, and its exact mechanism during IHCC progression deserves further investigation.
Keywords: intrahepatic cholangiocarcinomas, biomarker, TBX4, HSP60, DJ-1
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.